EXACT Therapeutics AS announces interim results for first half 2022

OSLO/LONDON, SEPTEMBER 22nd 2022
September 22nd 2022: EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth: EXTX),
a clinical stage precision health company utilising Acoustic Cluster Therapy
(ACT®) across multiple therapeutic areas, today announces its interim results
for the first half 2022.
The Interim Report for the first half year 2022 is also available on the
company's website: www.exact-tx.com
For more information, please contact:
Dr Per Walday
Chief Executive Officer
EXACT-Tx
Email: per.walday@exact-tx.com

About EXACT-Tx
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and brain diseases. www.exact-tx.com
About ACT®
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the Company is oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
product classes.
Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.